Skip to main content
Clinical Trials/NCT04606225
NCT04606225UnknownNot Applicable

The Role of the Renin-angiotensin System in Emotion-memory Interactions

University of Electronic Science and Technology of China1 site in 1 country60 target enrollmentStarted: October 10, 2020Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
fMRI-based indices of neural activity during processing of emotional stimuli will be compared between the treatment groups

Study Overview

Brief Summary

The purpose of this study is to investigate whether a single dose of losartan (50 mg) can affect emotion-memory interaction in healthy humans and its underlying neural mechanisms.

Detailed Description

Animal models and initial findings in humans suggest a role of the renin-angiotensin system in cognitive and emotional processes. Accumulating evidence demonstrates modulatory effects of the angiotensin antagonist losartan in the domains of memory and emotional processing. Against this background the present study aims to investigate the behavioral and neural effects of a single dose of losartan on emotional processing and emotion-memory integration in healthy subjects. In a double-blind, between-subject, placebo-controlled pharmaco-fMRI experiment, 60 male participants will be randomized to a single dose of losartan (50 mg) or placebo, and encode emotional pictures during fMRI (scheduled 90 minutes after drug administration). Then 24 hours post fMRI participants will finish a surprise recognition memory test to estimate the emotion effects on subsequent memory.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 30 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy subjects without past or current psychiatric or neurological disorders
  • Right-handedness
  • Normal or corrected-normal version

Exclusion Criteria

  • History of head injury
  • Medical or psychiatric illness
  • Hypertension
  • General cardio-vascular alteration or diseases
  • Allergy against medications
  • Visual or motor impairments
  • Claustrophobia
  • Drug addiction
  • Nicotine dependence
  • FMRI contradictions

Arms & Interventions

Losartan group

Experimental

Drug: Losartan

Intervention: Losartan (Drug)

Placebo group

Placebo Comparator

Drug: Placebo Oral Tablet

Intervention: Placebo Oral Tablet (Drug)

Outcomes

Primary Outcomes

fMRI-based indices of neural activity during processing of emotional stimuli will be compared between the treatment groups

Time Frame: 120 to 150 minutes after treatment

Neural activation during processing of emotional pictures will be assessed by functional magnetic resonance imaging (fMRI). The fMRI data will be analyzed by a Generalized Linear Model approach. Effects of treatment will be determined by comparing the losartan-treated group with the placebo-treated group.

fMRI-based indices of neural activity for subsequently successfully remembered as compared to non-remembered stimuli will be compared between the treatment groups

Time Frame: 120 to 150 minutes after treatment

Neural activation for stimuli that are successfully remembered after an interval of 24hours will be compared to stimuli that are not successfully remembered. Neural activity between the subsequently remembered and non-remembered stimuli will be assessed by functional magnetic resonance imaging (fMRI) acquired during the initial encoding of the stimuli. The fMRI data will be analyzed by a Generalized Linear Model approach. Effects of treatment will be determined by comparing the losartan-treated group with the placebo-treated group.

Secondary Outcomes

  • Self-Assessment Manikin (SAM) ratings of arousal of the stimuli will be compared between the treatment groups(120 to 150 minutes after treatment)
  • Self-Assessment Manikin (SAM) ratings of valence of the stimuli will be compared between the treatment groups(120 to 150 minutes after treatment)
  • Memory performance in terms of correctly recognized stimuli will be compared between the treatment groups(24 hours after treatment)

Investigators

Sponsor
University of Electronic Science and Technology of China
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Benjamin Becker

Professor

University of Electronic Science and Technology of China

Study Sites (1)

Loading locations...

Similar Trials